Bone scanner study pulled before starting: no participants enrolled
NCT ID NCT04253340
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study was designed to see if a special bone scanner (bone mineral analyser) could predict how well osteoporotic women would respond to a zoledronic acid infusion. The plan was to measure bone texture and density before and one year after treatment. However, the study was withdrawn before enrolling any participants, so no results are available.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- Active substance
- zoledronic acid
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Not a phased trial
Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.
- Expected to start
-
Mar 2020
An estimate. Start dates often move.
- Expected to finish
-
Mar 2023
An estimate. End dates often move.
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
18 to 85 years
- Sex
-
Female participants only
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: * Women \< 85 years old * Postmenopausal women (amenorrhea for more than 12 months), a confirmation diagnosis should be obtained (amenorrhea for at least 12 months before the inclusion visit). * Post-menopausal osteoporosis with one or more severe fractures (upper end of the humerus, femur, or tibia; 3 adjacent ribs; lower end of the femur; thoracic or lumbar spine; pelvis), or T score \<-3 which justifies setting up a bisphosphonate treatment * Affiliated to social security Exclusion Criteria: * Contraindication to zoledronic acid (allergy to the product, creatinine clearance \<35 ml / min, hypocalcemia, open and unhealed lesions of the soft tissues of the mouth) * Hormone replacement therapy taken in the last 12 months * Osteoprotective treatment (bisphosphonates, teriparatide, raloxifene, strontium ralenate or denosumab) taken in the last 12 months * Secondary osteoporosis: hyperthyroidism, hyperparathyroidism, long-term corticosteroid therapy, hypercorticism, hypogonadism, treatment with anti aromatases / LHRH analogues, neoplastic pathology (solid or hemopathy) * History of bilateral wrist or femur fracture * Person deprived of liberty by an administrative or judicial decision or person placed under the protection of justice / guardianship or curatorship * Patient participating in another trial / having participated in another trial within 6 months
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Osteoporosis are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Pregnancy hormone hCG may hold clues to bone and gland health
- Simple scan mistakes may skew osteoporosis diagnoses
- Can a new antibody rebuild bone in osteoporosis?
- Can better posture strengthen the pelvic floor in osteoporosis?
- Could exercise be the key to stronger bones in women?
- Robotic legs may help rebuild bone in people with spinal cord injury